Sumant Kulkarni
Stock Analyst at Canaccord Genuity
(1.32)
# 3,401
Out of 4,873 analysts
112
Total ratings
34.38%
Success rate
-11.41%
Average return
Main Sectors:
Stocks Rated by Sumant Kulkarni
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SAGE Sage Therapeutics | Maintains: Hold | $8 → $8.5 | $9.22 | -7.81% | 6 | Jun 17, 2025 | |
| ANVS Annovis Bio | Maintains: Buy | $26 → $17 | $3.06 | +455.56% | 3 | May 15, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $158 → $160 | $128.18 | +24.82% | 16 | May 6, 2025 | |
| BIIB Biogen | Maintains: Buy | $265 → $220 | $126.31 | +74.17% | 21 | May 2, 2025 | |
| CRVO CervoMed | Maintains: Buy | $12 → $21 | $6.81 | +208.37% | 5 | Mar 18, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $23 → $25 | $9.16 | +173.07% | 6 | Mar 13, 2025 | |
| VYGR Voyager Therapeutics | Maintains: Buy | $14 → $12 | $3.00 | +300.00% | 5 | Mar 13, 2025 | |
| CMPS COMPASS Pathways | Maintains: Buy | $23 → $15 | $2.53 | +492.89% | 3 | Feb 28, 2025 | |
| CYBN Cybin | Maintains: Buy | $86 → $73 | $7.84 | +831.12% | 7 | Feb 12, 2025 | |
| BTAI BioXcel Therapeutics | Maintains: Buy | $112 → $80 | $1.73 | +4,524.28% | 7 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $28 | $12.54 | +123.29% | 4 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 | $2.11 | +421.33% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $86 → $83 | $4.12 | +1,914.56% | 5 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $14 | $7.15 | +95.94% | 1 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $20 | $11.51 | +73.76% | 3 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $33 | $22.42 | +47.22% | 13 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $150 | $14.77 | +915.57% | 4 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $17.09 | - | 2 | Jan 31, 2017 |
Sage Therapeutics
Jun 17, 2025
Maintains: Hold
Price Target: $8 → $8.5
Current: $9.22
Upside: -7.81%
Annovis Bio
May 15, 2025
Maintains: Buy
Price Target: $26 → $17
Current: $3.06
Upside: +455.56%
Neurocrine Biosciences
May 6, 2025
Maintains: Buy
Price Target: $158 → $160
Current: $128.18
Upside: +24.82%
Biogen
May 2, 2025
Maintains: Buy
Price Target: $265 → $220
Current: $126.31
Upside: +74.17%
CervoMed
Mar 18, 2025
Maintains: Buy
Price Target: $12 → $21
Current: $6.81
Upside: +208.37%
Zevra Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $23 → $25
Current: $9.16
Upside: +173.07%
Voyager Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $14 → $12
Current: $3.00
Upside: +300.00%
COMPASS Pathways
Feb 28, 2025
Maintains: Buy
Price Target: $23 → $15
Current: $2.53
Upside: +492.89%
Cybin
Feb 12, 2025
Maintains: Buy
Price Target: $86 → $73
Current: $7.84
Upside: +831.12%
BioXcel Therapeutics
Jan 6, 2025
Maintains: Buy
Price Target: $112 → $80
Current: $1.73
Upside: +4,524.28%
Nov 18, 2024
Maintains: Buy
Price Target: $31 → $28
Current: $12.54
Upside: +123.29%
Nov 18, 2024
Maintains: Buy
Price Target: $11
Current: $2.11
Upside: +421.33%
Nov 14, 2024
Maintains: Buy
Price Target: $86 → $83
Current: $4.12
Upside: +1,914.56%
Sep 16, 2024
Maintains: Buy
Price Target: $16 → $14
Current: $7.15
Upside: +95.94%
May 7, 2024
Maintains: Buy
Price Target: $21 → $20
Current: $11.51
Upside: +73.76%
Mar 12, 2024
Maintains: Buy
Price Target: $40 → $33
Current: $22.42
Upside: +47.22%
Aug 3, 2021
Maintains: Buy
Price Target: $101 → $150
Current: $14.77
Upside: +915.57%
Jan 31, 2017
Upgrades: Buy
Price Target: n/a
Current: $17.09
Upside: -